Comparative analysis of staging systems in AL amyloidosis

Leukemia. 2019 Mar;33(3):811-814. doi: 10.1038/s41375-018-0370-z. Epub 2019 Jan 23.

Authors

Eli Muchtar¹, Terry M Therneau², Dirk R Larson², Morie A Gertz¹, Martha Q Lacy¹, Francis K Buadi¹, David Dingli¹, Suzanne R Hayman¹, Prashant Kapoor¹, Wilson Gonsalves¹, Taxiarchis V Kourelis¹, Rahma Warsame¹, Amie Fonder¹, Miriam Hobbs¹, Yi Lisa Hwa¹, Nelson Leung^{1

3}, Stephen Russell¹, John A Lust¹, Yi Lin¹, Ronald S Go¹, Steven Zeldenrust¹, Robert A Kyle¹, S Vincent Rajkumar¹, Shaji K Kumar¹, Angela Dispenzieri⁴

Affiliations

¹ Division of Hematology, Mayo Clinic, Rochester, MN, USA.
² Division of Biostatistics, Department of Medicine, College of Medicine, Mayo Clinic, Rochester, MN, USA.
³ Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.
⁴ Division of Hematology, Mayo Clinic, Rochester, MN, USA. dispenzieri.angela@mayo.edu.

PMID: 30675009
DOI: 10.1038/s41375-018-0370-z

No abstract available

Publication types

Comparative Study
Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Cohort Studies
Female
Humans
Immunoglobulin Light-chain Amyloidosis / metabolism
Immunoglobulin Light-chain Amyloidosis / pathology*
Male
Middle Aged
Neoplasm Staging / methods*
Prognosis